Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVRNASDAQ:DXRNASDAQ:LUCDNASDAQ:PDEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$3.64+12.7%$3.96$2.34▼$8.79$131.27MN/A204,872 shs191,576 shsDXRDaxor$7.74-3.3%$7.73$6.55▼$10.00$37.44M-0.216,232 shs1,563 shsLUCDLucid Diagnostics$1.59+19.5%$1.35$0.68▼$1.80$172.02M1.28526,715 shs3.04 million shsPDEXPro-Dex$46.24+1.4%$53.03$16.84▼$70.26$150.79M0.3730,316 shs32,196 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global0.00%-12.29%-29.18%-55.88%+363,999,900.00%DXRDaxor0.00%+1.04%-0.39%+6.91%-19.29%LUCDLucid Diagnostics0.00%+26.19%+19.55%+8.90%+73.77%PDEXPro-Dex0.00%+7.24%-30.90%+44.50%+135.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVRAnteris Technologies GlobalN/AN/AN/AN/AN/AN/AN/AN/ADXRDaxor3.7827 of 5 stars3.55.00.00.00.63.30.0LUCDLucid Diagnostics3.0428 of 5 stars3.65.00.00.02.31.70.6PDEXPro-Dex2.5877 of 5 stars2.52.00.00.03.52.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVRAnteris Technologies Global 3.00Buy$16.50353.30% UpsideDXRDaxor 3.00Buy$25.00223.00% UpsideLUCDLucid Diagnostics 3.20Buy$3.50120.13% UpsidePDEXPro-Dex 3.00Buy$52.0012.46% UpsideCurrent Analyst Ratings BreakdownLatest DXR, PDEX, LUCD, and AVR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.005/14/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.004/21/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.504/11/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/26/2025LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.003/25/2025LUCDLucid DiagnosticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.003/24/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.50 ➝ $3.003/17/2025DXRDaxorAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.75 ➝ $25.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVRAnteris Technologies Global$2.71M48.42N/AN/AN/A∞DXRDaxor$2.13M17.57N/AN/AN/A∞LUCDLucid Diagnostics$4.17M41.22N/AN/A($0.47) per share-3.38PDEXPro-Dex$64.12M2.35$1.33 per share34.81$9.76 per share4.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVRAnteris Technologies GlobalN/AN/A0.00N/AN/AN/AN/AN/AN/ADXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/ALUCDLucid Diagnostics-$52.67M-$1.34N/AN/AN/A-1,069.87%N/A-123.54%8/11/2025 (Estimated)PDEXPro-Dex$2.13M$2.8023.0122.45N/A11.06%21.68%12.40%N/ALatest DXR, PDEX, LUCD, and AVR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025AVRAnteris Technologies GlobalN/A-$0.61N/A-$0.61N/AN/A5/1/2025Q3 2025PDEXPro-Dex$0.47$0.98+$0.51$0.98$17.70 million$17.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVRAnteris Technologies GlobalN/AN/AN/AN/AN/ADXRDaxor$0.030.39%N/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVRAnteris Technologies GlobalN/AN/AN/ADXRDaxorN/AN/AN/ALUCDLucid DiagnosticsN/A1.181.14PDEXPro-Dex0.332.581.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVRAnteris Technologies GlobalN/ADXRDaxor1.34%LUCDLucid Diagnostics74.01%PDEXPro-Dex15.28%Insider OwnershipCompanyInsider OwnershipAVRAnteris Technologies GlobalN/ADXRDaxor59.00%LUCDLucid Diagnostics6.80%PDEXPro-Dex47.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVRAnteris Technologies Global13836.06 millionN/AN/ADXRDaxor374.84 million1.98 millionNot OptionableLUCDLucid Diagnostics70108.19 million54.12 millionNo DataPDEXPro-Dex1403.26 million1.71 millionNot OptionableDXR, PDEX, LUCD, and AVR HeadlinesRecent News About These CompaniesOMERS ADMINISTRATION Corp Takes Position in Pro-Dex, Inc. (NASDAQ:PDEX)May 22 at 4:23 AM | marketbeat.comAre Pro-Dex, Inc.'s (NASDAQ:PDEX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?May 20, 2025 | finance.yahoo.comPro-Dex (NASDAQ:PDEX) Share Price Crosses Below Two Hundred Day Moving Average - Should You Sell?May 15, 2025 | marketbeat.com9,260 Shares in Pro-Dex, Inc. (NASDAQ:PDEX) Bought by Marshall Wace LLPMay 6, 2025 | marketbeat.comPro-Dex: Crash After Strong Earnings Leads To A Buying OpportunityMay 5, 2025 | seekingalpha.comHere's Why Pro-Dex (NASDAQ:PDEX) Has Caught The Eye Of InvestorsMay 4, 2025 | uk.finance.yahoo.com683 Capital Management LLC Makes New $739,000 Investment in Pro-Dex, Inc. (NASDAQ:PDEX)May 4, 2025 | marketbeat.comShort Interest in Pro-Dex, Inc. (NASDAQ:PDEX) Rises By 61.9%May 2, 2025 | marketbeat.comPro-Dex, Inc. (PDEX) Q3 Earnings Surpass EstimatesMay 1, 2025 | zacks.comPro-Dex, Inc. Announces Fiscal 2025 Third Quarter and Nine-Month ResultsMay 1, 2025 | accessnewswire.comRussell Investments Group Ltd. Buys Shares of 6,999 Pro-Dex, Inc. (NASDAQ:PDEX)April 27, 2025 | marketbeat.comPro-Dex (PDEX) Expected to Announce Earnings on ThursdayApril 26, 2025 | marketbeat.comProDex (PDEX) Moves 5.1% Higher: Will This Strength Last?April 25, 2025 | zacks.comTake the Zacks Approach to Beat the Markets: Pro-Dex, Brookdale Senior Living, Coca-Cola in FocusApril 21, 2025 | zacks.comProDex (PDEX) Surges 7.4%: Is This an Indication of Further Gains?April 3, 2025 | zacks.comPro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 842 SharesApril 2, 2025 | insidertrades.comPro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 836 SharesApril 1, 2025 | insidertrades.comInsider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 3,096 Shares of StockMarch 28, 2025 | insidertrades.comInsider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 5,151 Shares of StockMarch 18, 2025 | insidertrades.comWith 38% ownership in Pro-Dex, Inc. (NASDAQ:PDEX), hedge funds investors have a lot riding on the businessMarch 11, 2025 | finance.yahoo.comProDex (PDEX) Upgraded to Strong Buy: Here's What You Should KnowFebruary 28, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDXR, PDEX, LUCD, and AVR Company DescriptionsAnteris Technologies Global NASDAQ:AVR$3.64 +0.41 (+12.69%) As of 05/23/2025 04:00 PM EasternAnteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.Daxor NASDAQ:DXR$7.74 -0.26 (-3.25%) As of 05/23/2025 03:51 PM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Lucid Diagnostics NASDAQ:LUCD$1.59 +0.26 (+19.55%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.64 +0.04 (+2.83%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Pro-Dex NASDAQ:PDEX$46.24 +0.62 (+1.36%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$46.25 +0.01 (+0.02%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Alphabet Stock Lags—But Waymo May Be Its Hidden Driver Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
